Critical analysis of rituximab-induced serological changes in connective tissue diseases

被引：30
作者：
Cornec, D. [1 ,2 ,3 ,4 ]
Avouac, J. [5 ]
Youinou, P. [1 ,2 ,4 ]
Saraux, A. [1 ,2 ,3 ]
机构：
[1] Univ Brest, EA2216, Brest, France
[2] Univ Brest, IRF148, Brest, France
[3] Hop la Cavale Blanche, CHU, Rheumatol Unit, Brest, France
[4] Hop Morvan, Immunol Lab, Brest, France
[5] Hop Cochin, Dept Rheumatol, F-75674 Paris, France
来源：
AUTOIMMUNITY REVIEWS | 2009年 / 8卷 / 06期
关键词：
Rituximab; Connective tissue diseases; Immunoglobulin; Autoantibody; BAFF; B lymphocyte; SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL DEPLETION; ACTIVE RHEUMATOID-ARTHRITIS; PRIMARY SJOGRENS-SYNDROME; ANTI-CD20; TREATMENT; AUTOIMMUNE-DISEASE; TREATED PATIENTS; SALIVARY-GLANDS; DOUBLE-BLIND; THERAPY;
D O I：
10.1016/j.autrev.2009.01.007
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A survey of PUBMED and EMBASE supplied 21 articles dealing with the effect of rituximab (RTX) on immunoglobulin (Ig) and autoantibodies (Abs) in nonorgan-systemic autoimmune diseases, and another 12 articles were found by hand search. No statistics could be performed due to the lack of numerical data in the articles. RTX tended to diminish total Ig but still within the normal ranges, more for IgM than IgG and IgA. Rheumatoid factor level decreased by 30 to 60% 3-6 months after RTX, whereas anti-cyclic citrullinated peptide Ab titers declined modestly. In contrast, anti-DNA and anti-C1q Ab levels showed a marked decrease, whereas the other anti-extractable nuclear antigens Ab (anti-SSA, SSB, SM, RNP...) were stable. There are claims for an increase in the BAFF level by approximately 2.5 to 3-fold at 3-4 months, and a return to pre-treatment value at 8-12 months. RTX-induced changes in the serum bring about new insights into mechanisms of action. Therefore, more attention should be paid to such parameters in clinical trials. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码：515 / 519
页数：5
相关论文
共 40 条
[11]   Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis - Evidence for a pathogenetic role of B cells [J].
De Vita, S ;
Zaja, F ;
Sacco, S ;
De Candia, A ;
Fanin, R ;
Ferraccioli, G .
ARTHRITIS AND RHEUMATISM, 2002, 46 (08) :2029-2033
[12]   Role of anti-DNA antibodies in the pathogenesis of lupus nephritis [J].
Deshmukh, Umesh S. ;
Bagavant, Harini ;
Fu, Shu Man .
AUTOIMMUNITY REVIEWS, 2006, 5 (06) :414-418
[13]   Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20) [J].
Devauchelle-Pensec, Valerie ;
Pennec, Yvon ;
Morvan, Johanne ;
Pers, Jacques-Olivier ;
Daridon, Capucine ;
Jousse-Joulin, Sandrine ;
Roudaut, Anne ;
Jamin, Christophe ;
Renaudineau, Yves ;
Roue, Isabelle Quintin ;
Cochener, Beatrice ;
Youinou, Pierre ;
Saraux, Alain .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (02) :310-317
[14]   Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes [J].
Edwards, JCW ;
Cambridge, G .
RHEUMATOLOGY, 2001, 40 (02) :205-211
[15]  
Edwards JCW, 1999, IMMUNOLOGY, V97, P188
[16]   The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial [J].
Emery, P ;
Fleischmann, R ;
Filipowicz-Sosnowska, A ;
Schechtman, J ;
Szczepanski, L ;
Kavanaugh, A ;
Racewicz, AJ ;
Van Vollenhoven, RF ;
Li, NF ;
Agarwal, S ;
Hessey, EW ;
Shaw, TM .
ARTHRITIS AND RHEUMATISM, 2006, 54 (05) :1390-1400
[17]   Treatment of refractory SLE with rituximab plus cyclophosphamide:: clinical effects, serological changes, and predictors of response [J].
Jonsdottir, T. ;
Gunnarsson, I. ;
Risselada, A. ;
Henriksson, E. W. ;
Klareskog, L. ;
van Vollenhoven, R. F. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) :330-334
[18]   Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results [J].
Kavanaugh, A. ;
Rosengren, S. ;
Lee, S. J. ;
Hammaker, D. ;
Firestein, G. S. ;
Kalunian, K. ;
Wei, N. ;
Boyle, D. L. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) :402-408
[19]   Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis [J].
Keystone, Edward ;
Fleischmann, Roy ;
Emery, Paul ;
Furst, Daniel E. ;
van Vollenhoven, Ronald ;
Bathon, Joan ;
Dougados, Maxime ;
Baldassare, Andrew ;
Ferraccioli, Gianfranco ;
Chubick, Andrew ;
Udell, James ;
Cravets, Matthew W. ;
Agarwal, Sunil ;
Cooper, Simon ;
Magrini, Fabio .
ARTHRITIS AND RHEUMATISM, 2007, 56 (12) :3896-3908
[20]   Improvement of refractory rheumatoid arthritis after depletion of B cells [J].
Kneitz, C ;
Wilhelm, M ;
Tony, HP .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2004, 33 (02) :82-86
1234